INMB - NASDAQ
INmune Bio, Inc.
$1.89
-1.3%INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
At a Glance
Live SnapshotINmune Bio, Inc. Management Team
Dr. Mark William Lowdell Ph.D.
Chief Scientific Officer & Chief Manufacturing Officer
Compensation
$246,692
Mr. Cory Randall Ellspermann
Interim Chief Financial Officer
Mr. David J. Moss M.B.A.
President, Chief Executive Officer, Treasurer, Secretary & Director
Compensation
$500,043
INmune Bio, Inc. Insider Positioning
During the last 12 months, there has been no insider trading activity reported for INMB.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
SEC Filings
INMB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | October 14, 2025 | November 18, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 21, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | May 29, 2024 | July 19, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 21, 2023 | June 01, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 19, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 26, 2021 | June 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | August 21, 2020 | September 30, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 09, 2019 | July 25, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.